{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:22:22Z","timestamp":1777724542330,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[1990,1,1]],"date-time":"1990-01-01T00:00:00Z","timestamp":631152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[1990,1]]},"abstract":"<jats:p>The clinical efficacy and safety of 3.75 or 7.5 mg leuprorelin acetate depot given subcutaneously once every 4 weeks was evaluated in a collaborative study of 81 patients with untreated prostatic cancer. Efficacy of treatment was assessed using criteria based on a meeting of the Prostatic Cancer Study Group funded by the Japanese Ministry of Health and Welfare and using National Prostatic Cancer Project criteria. Japanese criteria enabled evaluation of individual parameters, unlike the National Prostatic Cancer Project System which classified a patient as unevaluable if one evaluation parameter was unavailable. Leuprorelin acetate depot suppressed serum luteinizing hormone, follicle stimulating hormone and testosterone concentrations. Objective response rates of the prostate, bone mtastases, serum prostatic acid phosphatase and soft tissue metastases, and subjective dysuria and pain responses were comparable to those found with conventional hormone therapy. Leuprorelin acetate depot was well tolerated, with no significant differences in response to the two doses.<\/jats:p>\n                  <jats:p>L'efficacit\u00e9 clinique de l'ac\u00e9tate de leupror\u00e9line sous forme retard \u00e0 la dose de 3,75 ou 7,5 mg administr\u00e9 par voie sous-cutan\u00e9e une fois toutes les 4 semaines a \u00e9t\u00e9 \u00e9valu\u00e9e dans le cadre d'une \u00e9tude, portant sur 81 malades souffrant d'un cancer prostatique. L'efficacit\u00e9 du traitement a \u00e9t\u00e9 \u00e9valu\u00e9e en faisant appel \u00e0 des crit\u00e8res d\u00e9termin\u00e9s par le Prostatic Cancer Study Group (Groupe d'Etudes sur le Cancer Prostatique) fond\u00e9 par le Minist\u00e8re de la Sant\u00e9 du Japon et le National Prostatic Cancer Project (Projet National sur le Cancer Prostatique). Les crit\u00e8res janonais ont rendus possibles l'\u00e9valuation de param\u00e8tres individuels \u00e0 l'encontre du syst\u00e8me adopt\u00e9 par le Projet National sur le Cancer Prostatique qui a class\u00e9 un malade comme \u00e9tant non \u00e9valuable d\u00e8s que l'obtention d'un param\u00e8tre d'\u00e9valuation n'\u00e9tait pas possible. L'ac\u00e9tate de leupror\u00e9line retard induit la r\u00e9duction des concentrations plasmatiques en hormones lut\u00e9inisantes, en hormones de stimulation des follicules (FSH) et en test\u00e9rone. Les taux objectifs d'am\u00e9lioration de la prostate, des m\u00e9tastases des tissus mous et des taux plasmatiques de phosphatase acide prostatique, de la dysurie subjective et des degr\u00e9s de douleurs \u00e9taient comparables aux hormonoth\u00e9rapies conventionnelles. L'ac\u00e9tate de leupror\u00e9line retard a \u00e9t\u00e9 bien tol\u00e9r\u00e9, et n'a pas induit de diff\u00e9rences significatives dans la r\u00e9ponse obtenue aux deux doses administr\u00e9es.<\/jats:p>\n                  <jats:p>L'efficacia cl\u00ednica di 3,75 o 7,5 mg di leuprorelin acetato, in preparazione \u201critardo\u201d, somministrato per via sottocutanea ogni 4 settimane \u00e8 stata valutata nel corso di uno studio collaborativo condotto su 81 pazienti ammalati di cancro alla prostata. L'efficacia del trattamento \u00e8 stata valutata adottando dei criteri scaturiti da una riunione del Gruppo di Studio sul Cancro della Prostata, fondato dal Ministero della Sanit \u00e0 giapponese, nonch\u00e8 dei criteri stabiliti dal \u201cNational Prostatic Cancer Project\u201d. I criteri elaborad in Giappone hanno consentito la valutazione dei singoli paramtri a differenza del sistema del \u201cNational Prostatic Cancer Project\u201d, nell'ambito del quale un paziente veniva classificato corne non valutabile nel caso che uno dei parametri necessari alla valutazione non fosse disponibile. Il leuprorelin acetato, in preparazione \u201critardo\u201d, ha soppresso le concentrazioni seriche di ormone luteinizzante, ormone follicolostimolante e testosterone. I tassi di risposta oggettivi, relativi alle metastasi prostatiche, ossee, alla concentrazione serica di fosfatasi acida prostatica ed alle metastasi dei tessuti molli, nonch\u00e8 le risposte soggettive relative alla disuria ed al dolore, sono risultati comparabili a quelli ottenuti con una convenzionale terapia ormonale. Il leuprorelin acetato, in preparazione \u201critardo\u201d, \u00e8 stato ben tollerato, senza significative differenze nella risposta alle due dosi.<\/jats:p>","DOI":"10.1177\/03000605900180s114","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T15:23:24Z","timestamp":1483629804000},"page":"90-102","source":"Crossref","is-referenced-by-count":9,"title":["Leuprorelin Acetate Depot: Results of a Multicentre Japanese Trial"],"prefix":"10.1177","volume":"18","author":[{"given":"H.","family":"Akaza","sequence":"first","affiliation":[{"name":"University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Aso","sequence":"additional","affiliation":[{"name":"University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Koiso","sequence":"additional","affiliation":[{"name":"University of Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fuse","sequence":"additional","affiliation":[{"name":"University of Chiba School of Medicine, Chibashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Isurugi","sequence":"additional","affiliation":[{"name":"Tokyo Teishin Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. O","family":"Kada","sequence":"additional","affiliation":[{"name":"Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Usami","sequence":"additional","affiliation":[{"name":"The Centre for Adult Diseases, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kotake","sequence":"additional","affiliation":[{"name":"The Centre for Adult Diseases, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Okayama University Medical School, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ueda","sequence":"additional","affiliation":[{"name":"Kyushu University, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Niijima","sequence":"additional","affiliation":[{"name":"Tokyo Seamen's Insurance Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Tap-144-Sr Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1990,1,1]]},"reference":[{"key":"bibr1-03000605900180S114","first-page":"243","volume-title":"EORTC Genitourinary Group Monograph 5: Progress and Controversies in Oncology Urology","author":"Jones WG","year":"1988"},{"key":"bibr2-03000605900180S114","first-page":"894","volume":"33","author":"Akaza H","year":"1987","journal-title":"Acta Urol Jpn"},{"key":"bibr3-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990010313"},{"key":"bibr4-03000605900180S114","unstructured":"Japanese Urological Association and Japanese Patholgical Society: General Rules for Clinical and Pathological Studies on Prostate Cancer, Tokyo: 1985."},{"key":"bibr5-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(60)90137-5"},{"key":"bibr6-03000605900180S114","first-page":"1389","volume":"33","author":"Isaka S","year":"1987","journal-title":"Acta Urol Jpn"},{"key":"bibr7-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/63.3.615"},{"key":"bibr8-03000605900180S114","first-page":"81","volume":"31","author":"Fuse H","year":"1985","journal-title":"Acta Urol Jpn"},{"key":"bibr9-03000605900180S114","first-page":"159","volume":"17","author":"Wang MC","year":"1979","journal-title":"lnvest Urol"},{"key":"bibr10-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)54980-0"},{"key":"bibr11-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)51917-5"},{"key":"bibr12-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411153112004"},{"key":"bibr13-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990040603"},{"key":"bibr14-03000605900180S114","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-7-1-67"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605900180S114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605900180S114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:11Z","timestamp":1777459211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605900180S114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,1]]},"references-count":14,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[1990,1]]}},"alternative-id":["10.1177\/03000605900180S114"],"URL":"https:\/\/doi.org\/10.1177\/03000605900180s114","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,1]]}}}